BI’s Business Development Focus Remains On Early Collaboration
Executive Summary
Boehringer Ingelheim’s US business development head Ioannis Sapountzis outlines BI’s efforts to catch up with competitors in NASH and immuno-oncology via early-stage partnerships and licensing deals.
You may also be interested in...
136 Years And Counting: Boehringer Ingelheim Sees Advantage In Private Structure
The family-owned German pharma dates back to 1885 and tries to keep up with its publicly traded peers by not mimicking everything they do, but with a “value by innovation” focus.
Boehringer’s Philosophy Of Deal-Making: A Conversation With Ioannis Sapountzis And Scott DeWire
The German pharma’s top business development execs explain how they balance IO and targeted cancer therapy in their portfolio, views on major M&A and how to make deals during a global pandemic.
Boehringer Ingelheim Is Getting Bets In Early In IO Space
The head of the German family-owned firm's venture fund tells Scrip that investing very early in promising start-ups gives Boehringer Ingelheim "a little bit of a head start" on rival pharma companies in identifying technologies that could translate into therapies five years down the line .